These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37539477)

  • 1. Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross-sectional study of the National Covid Cohort Collaborative (N3C).
    Xiao X; Mehta HB; Curran J; Garibaldi BT; Alexander GC;
    Pharmacotherapy; 2023 Dec; 43(12):1251-1261. PubMed ID: 37539477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
    PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
    Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
    Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
    Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
    Park JJ; Kim H; Kim YK; Lee SS; Jung E; Lee JS; Lee J
    J Korean Med Sci; 2023 Oct; 38(42):e347. PubMed ID: 37904658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
    Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
    J Intensive Care Med; 2024 Aug; 39(8):742-750. PubMed ID: 38356292
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.
    Bose-Brill S; Hirabayashi K; Schwimmer E; Pajor NM; Rao S; Mejias A; Jhaveri R; Forrest CB; Bailey LC; Christakis DA; Thacker D; Hanley PC; Patel PB; Cogen JD; Block JP; Prahalad P; Lorman V; Lee GM;
    Hosp Pediatr; 2024 Aug; 14(8):e341-e348. PubMed ID: 39076115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
    Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
    Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients.
    Exquis N; Dionisi B; Samer CF; Rollason V; Curtin F; Zekry D; Graf C; Prendki V; Ing Lorenzini K
    Viruses; 2024 May; 16(6):. PubMed ID: 38932157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
    Giguère P; Deschenes MJ; Van Loon M; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
    Clin J Am Soc Nephrol; 2023 Jul; 18(7):913-919. PubMed ID: 37099447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
    Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir.
    Gerhart J; Draica F; Benigno M; Atkinson J; Reimbaeva M; Francis D; Baillon-Plot N; Sidhu GS; Damle BD
    AAPS J; 2023 Jul; 25(5):73. PubMed ID: 37468770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.